Migraine is a debilitating neurological condition affecting approximately 1 billion people globally, ranking as the second leading cause of disability worldwide by years lived with disability. Clinical trials have transformed acute and preventive treatment, with the CGRP pathway now the most actively targeted mechanism β€” producing anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and oral CGRP receptor antagonists (rimegepant, ubrogepant, atogepant) as approved agents, with numerous successors in trials.
Current trials investigate next-generation anti-CGRP agents with extended dosing intervals, combination preventive strategies for high-frequency migraine, valrocemide and Nav1.7 inhibitors for treatment-resistant patients, and non-pharmacological approaches including non-invasive vagus nerve stimulation (nVNS), TMS devices, and digital therapeutics. Trials also address cluster headache, chronic migraine, and vestibular migraine as distinct entities.
Migraine frequency (episodic: <15 headache days/month; chronic: ≥15/month) and medication overuse history are key eligibility criteria; biomarker-based enrichment trials use CGRP blood levels.
Frequently Asked Questions — migraine with aura Clinical Trials
How many clinical trials are currently recruiting for migraine with aura?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for migraine with aura, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for migraine with aura?
migraine with aura research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a migraine with aura clinical trial?
Eligibility criteria for migraine with aura trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
University of Florence 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: April 2026 ·
Data Methodology